Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY
Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...
Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech
Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and...
Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies
Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...
Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study
Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...
Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval
China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...
Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...
FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...
Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem
China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...
Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931
German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025
In a significant move to bolster foreign investment and enhance the country’s economic openness, the...
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the...
Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease
German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...
Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a...
Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens
UK-based RNA immunotherapy developer Epitopea announced a licensing and research cooperation agreement with US pharmaceutical...
Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
Germany-based Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has accepted its...
Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...
Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that its biosimilar of Roche’s Avastin (bevacizumab), Hanbeitai,...